Clinically, Hp2-2 is strongly associated with accelerated atherosclerosis in diabetic patients, evidenced by increased carotid intima-media thickness and oxidative stress markers. It also elevates risks for chronic kidney disease progression and end-stage renal disease, with a 3.84-fold increased hazard ratio for mortality in South Indian populations. Additionally, Hp2-2 correlates with familial epilepsy through hypohaptoglobinemia-mediated delayed hemoglobin clearance in neural tissues. Diagnostic applications include Hp phenotyping to stratify cardiovascular risk in diabetes, guiding targeted interventions like vitamin E supplementation. The phenotype's association with hypertension and overweight status further underscores its clinical relevance in metabolic disorders.

Common uses include metabolic studies, therapeutics research, IVD Assay standards, calibrators and controls, cardiovascular research, mass spectrometry, oxidative stress research.